Ulla Knorr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ulla Knorr has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Lars Vedel Kessing
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
35 shared publications - Maj Vinberg
Mental Health Center North Zealand, Copenhagen University Hospital
18 shared publications Lars Vedel Kessing
Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Department Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark
10 shared publications- Jørn Wetterslev
Private Office, Tuborg Sundpark, Hellerup, 2900, Denmark
8 shared publications - Kamilla Woznica Miskowiak
University of Copenhagen
8 shared publications - Christian Gluud
Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Department 7812, Copenhagen University Hospital ─ Rigshospitalet, Copenhagen, Denmark
7 shared publications
Latest Publications
- 19 February 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (2) , e70095
Cognitive Complaints in Bipolar Disorder: Relation to Estimated Illness‐Related Objective Cognitive Decline, Functioning, and Quality of Life
Objectives: Persons with bipolar disorder (BD) often present with cognitive complaints even in the absence of objective cognitive impairment as measured with neuropsychological tests. It remains unclear whether cognitive complaints reflect negative bias or illness‐related decline from premorbid functioning, affecting functioning and quality of life (QoL). Methods: Data from n = 498 persons with BD and n = 320 healthy controls (HC) were included from a database based on seven studies. We calculated IQ‐objective cognition discrepancy scores (−10 to +10; negative scores = lower cognitive performance than premorbid IQ, i.e., estimated ‘loss of function’) and subjective‐objective cognitive discrepancy scores (−10 to +10; negative scores = less subjective than objective difficulties; positive scores = more subjective than objective impairments). We investigated associations between these variables and subjective cognitive complaints, functioning, and QoL with multiple regression models. Results: Subjective cognitive complaints were associated with poorer global cognitive performance relative to premorbid IQ (i.e., estimated ‘loss of function’). More subjective than objective cognitive difficulties was associated with diminished functioning and QoL. A similar association was seen for objective cognitive performance. Conclusions: Subjective complaints may indicate a decline from premorbid cognitive function, even if objective cognitive performance is within the normal range after illness onset. More subjective than objective impairment correlates with poorer functioning and QoL. Hence, cognitive management initiatives should be centered around patients with cognitive complaints independent of objective cognitive status.
- 19 February 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (2) , e70095
Cognitive Complaints in Bipolar Disorder: Relation to Estimated Illness‐Related Objective Cognitive Decline, Functioning, and Quality of Life
Objectives: Persons with bipolar disorder (BD) often present with cognitive complaints even in the absence of objective cognitive impairment as measured with neuropsychological tests. It remains unclear whether cognitive complaints reflect negative bias or illness‐related decline from premorbid functioning, affecting functioning and quality of life (QoL). Methods: Data from n = 498 persons with BD and n = 320 healthy controls (HC) were included from a database based on seven studies. We calculated IQ‐objective cognition discrepancy scores (−10 to +10; negative scores = lower cognitive performance than premorbid IQ, i.e., estimated ‘loss of function’) and subjective‐objective cognitive discrepancy scores (−10 to +10; negative scores = less subjective than objective difficulties; positive scores = more subjective than objective impairments). We investigated associations between these variables and subjective cognitive complaints, functioning, and QoL with multiple regression models. Results: Subjective cognitive complaints were associated with poorer global cognitive performance relative to premorbid IQ (i.e., estimated ‘loss of function’). More subjective than objective cognitive difficulties was associated with diminished functioning and QoL. A similar association was seen for objective cognitive performance. Conclusions: Subjective complaints may indicate a decline from premorbid cognitive function, even if objective cognitive performance is within the normal range after illness onset. More subjective than objective impairment correlates with poorer functioning and QoL. Hence, cognitive management initiatives should be centered around patients with cognitive complaints independent of objective cognitive status.
- 8 March 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 184, 288-296
Associations between cerebrospinal fluid synaptic protein biomarkers and cognitive function in bipolar disorder
- 8 March 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 184, 288-296
Associations between cerebrospinal fluid synaptic protein biomarkers and cognitive function in bipolar disorder
- Open Access
- 28 January 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 375, 239-248
Cognitive hierarchy in mood disorders and relations to daily functioning
- 28 January 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 375, 239-248
Open AccessCognitive hierarchy in mood disorders and relations to daily functioning
- Open Access
- 7 May 2024
- Published by Elsevier in Journal of Affective Disorders
- Vol. 358, 250-259
Cerebrospinal fluid synaptic biomarker changes in bipolar disorder – A longitudinal case-control study
- 7 May 2024
- Published by Elsevier in Journal of Affective Disorders
- Vol. 358, 250-259
Open AccessCerebrospinal fluid synaptic biomarker changes in bipolar disorder – A longitudinal case-control study
- Open Access
- 19 March 2024
- Published by Springer Nature in Research Square
Associations Between Cerebrospinal Fluid Synaptic Protein Biomarkers and Cognitive Function in Bipolar Disorder
This study is the first to investigate the association between a comprehensive panel of cerebrospinal fluid (CSF) synaptic protein biomarkers and cognitive function utilizing data from a prospective cohort study including N = 59 patients with bipolar disorder (BD) and N = 37 healthy control individuals (HC). Biomarkers of synaptic dysfunction were analyzed by targeted mass spectrometry. They included neuronal pentraxin (NPTX)1, NPTX2, 14-3-3 proteins, AP-2 complex subunit-beta, beta-synuclein, complexin-2, gamma-synuclein, NPTX receptor, phosphatidylethanolamine-binding proteins, rab GDP dissociation inhibitor-alpha, syntaxins-1B and 7. The primary cognition measure was a global cognitive composite score based on neuropsychological tests probing verbal learning and memory, executive function, psychomotor speed, and sustained attention, respectively. Our primary hypothesis was that levels of NPTX1 and NPTX2 were associated with global cognition and verbal memory after adjustment for age, sex, and follow-up time as potential confounders. The study revealed consistent positive associations between CSF protein concentrations of NPTX1 and NPTX2 and global cognitive function. However, only the association with a tryptic peptide from NPTX2 (VAELEDEK) remained statistically significant after adjustment for multiple testing. In contrast, no consistent trends and no significant relationships were found between NPTX1 and NPTX2 and the verbal learning and memory domain. In exploratory analyses, NPTXs showed positive associations with sustained attention, and the NPTX receptor showed a positive association with global cognition scores. Similar trends were found in BD patients and HC individuals, although results remain statistically uncertain, and a spurious finding cannot be ruled out due to multiple testing. In summary, the study provides novel evidence for a potentially pivotal role of CSF synaptic proteins, particularly NPTX1, NPTX2, and NPTX receptor, in shaping global cognitive function across BD and HC populations and increases our understanding of the neurobiological foundations for cognitive functions across diagnostic boundaries.
- 19 March 2024
- Published by Springer Nature in Research Square
Open AccessAssociations Between Cerebrospinal Fluid Synaptic Protein Biomarkers and Cognitive Function in Bipolar Disorder
This study is the first to investigate the association between a comprehensive panel of cerebrospinal fluid (CSF) synaptic protein biomarkers and cognitive function utilizing data from a prospective cohort study including N = 59 patients with bipolar disorder (BD) and N = 37 healthy control individuals (HC). Biomarkers of synaptic dysfunction were analyzed by targeted mass spectrometry. They included neuronal pentraxin (NPTX)1, NPTX2, 14-3-3 proteins, AP-2 complex subunit-beta, beta-synuclein, complexin-2, gamma-synuclein, NPTX receptor, phosphatidylethanolamine-binding proteins, rab GDP dissociation inhibitor-alpha, syntaxins-1B and 7. The primary cognition measure was a global cognitive composite score based on neuropsychological tests probing verbal learning and memory, executive function, psychomotor speed, and sustained attention, respectively. Our primary hypothesis was that levels of NPTX1 and NPTX2 were associated with global cognition and verbal memory after adjustment for age, sex, and follow-up time as potential confounders. The study revealed consistent positive associations between CSF protein concentrations of NPTX1 and NPTX2 and global cognitive function. However, only the association with a tryptic peptide from NPTX2 (VAELEDEK) remained statistically significant after adjustment for multiple testing. In contrast, no consistent trends and no significant relationships were found between NPTX1 and NPTX2 and the verbal learning and memory domain. In exploratory analyses, NPTXs showed positive associations with sustained attention, and the NPTX receptor showed a positive association with global cognition scores. Similar trends were found in BD patients and HC individuals, although results remain statistically uncertain, and a spurious finding cannot be ruled out due to multiple testing. In summary, the study provides novel evidence for a potentially pivotal role of CSF synaptic proteins, particularly NPTX1, NPTX2, and NPTX receptor, in shaping global cognitive function across BD and HC populations and increases our understanding of the neurobiological foundations for cognitive functions across diagnostic boundaries.
- Open Access
- 16 January 2024
- Published by Springer Nature in International Journal of Bipolar Disorders
- Vol. 12 (1) , 1-12
Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case–control study of patients with bipolar disorder and healthy control individuals
Background: Abnormalities in cerebrospinal fluid (CSF)-amyloid-beta (Aβ)42, CSF-Aβ40, CSF-Aβ38, CSF-soluble amyloid precursor proteins α and β, CSF-total-tau, CSF-phosphorylated-tau, CSF-neurofilament light protein (NF-L), CSF-neurogranin, plasma-Aβ42, plasma-Aβ40, plasma-total-tau, plasma-NF-L and, serum-S100B during affective episodes may reflect brain changes that could impact cognitive function in patients with bipolar disorder (BD). The study aimed to investigate the association between these biomarkers indicative of Alzheimer’s disease and those reflecting neurodegeneration alongside their impact on cognitive function in patients with BD and healthy control individuals (HC). The primary hypothesis was that GL and VL would increase with increasing levels of CSF-Aβ42 based on data from T0 and T3 in BD and HC jointly. Methods: In a prospective, longitudinal case–control study euthymic patients with BD (N = 85) and HC (N = 44) were evaluated with clinical assessment and neuropsychological testing at baseline (T0) and during euthymia after a year (T3). Patients’ affective states were recorded weekly as euthymic, subthreshold level, major depression, or (hypo)mania. If an episode occurred during follow-up, the patient was also assessed in post-episode euthymia. Cognitive performance was measured as a global cognitive score (GL) for four cognitive domains including verbal learning and memory (VL). Results: Estimated in a linear mixed model GL increased with 0.001 for each increase of 1 pg/ml of CSF-Aβ42 (97.5%, CI 0.00043–0.0018, adjusted-p = 0.0005) while VL increased by 0.00089 (97.5%, CI 0.00015–0.0018, adjusted-p = 0.045) in BD and HC jointly. The association was weak, however stronger in patients with BD compared to HC. Associations between other biomarkers including CSF-neurogranin, and cognitive domains were overall weak, and none remained significant after adjustment for multiple testing. Limitations: Modest sample size. A complete data set regarding both CSF-AB-42 and cognitive test scores was obtained from merely 61 patients with BD and 38 HC individuals. Conclusion: CSF-Aβ42 may be associated with cognitive dysfunction in patients with BD and HC individuals. The association appeared to be stronger in BD but with overlapping confidence intervals. Hence it remains uncertain whether the association is a general phenomenon or driven by BD.
- 16 January 2024
- Published by Springer Nature in International Journal of Bipolar Disorders
- Vol. 12 (1) , 1-12
Open AccessBiomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case–control study of patients with bipolar disorder and healthy control individuals
Background: Abnormalities in cerebrospinal fluid (CSF)-amyloid-beta (Aβ)42, CSF-Aβ40, CSF-Aβ38, CSF-soluble amyloid precursor proteins α and β, CSF-total-tau, CSF-phosphorylated-tau, CSF-neurofilament light protein (NF-L), CSF-neurogranin, plasma-Aβ42, plasma-Aβ40, plasma-total-tau, plasma-NF-L and, serum-S100B during affective episodes may reflect brain changes that could impact cognitive function in patients with bipolar disorder (BD). The study aimed to investigate the association between these biomarkers indicative of Alzheimer’s disease and those reflecting neurodegeneration alongside their impact on cognitive function in patients with BD and healthy control individuals (HC). The primary hypothesis was that GL and VL would increase with increasing levels of CSF-Aβ42 based on data from T0 and T3 in BD and HC jointly. Methods: In a prospective, longitudinal case–control study euthymic patients with BD (N = 85) and HC (N = 44) were evaluated with clinical assessment and neuropsychological testing at baseline (T0) and during euthymia after a year (T3). Patients’ affective states were recorded weekly as euthymic, subthreshold level, major depression, or (hypo)mania. If an episode occurred during follow-up, the patient was also assessed in post-episode euthymia. Cognitive performance was measured as a global cognitive score (GL) for four cognitive domains including verbal learning and memory (VL). Results: Estimated in a linear mixed model GL increased with 0.001 for each increase of 1 pg/ml of CSF-Aβ42 (97.5%, CI 0.00043–0.0018, adjusted-p = 0.0005) while VL increased by 0.00089 (97.5%, CI 0.00015–0.0018, adjusted-p = 0.045) in BD and HC jointly. The association was weak, however stronger in patients with BD compared to HC. Associations between other biomarkers including CSF-neurogranin, and cognitive domains were overall weak, and none remained significant after adjustment for multiple testing. Limitations: Modest sample size. A complete data set regarding both CSF-AB-42 and cognitive test scores was obtained from merely 61 patients with BD and 38 HC individuals. Conclusion: CSF-Aβ42 may be associated with cognitive dysfunction in patients with BD and HC individuals. The association appeared to be stronger in BD but with overlapping confidence intervals. Hence it remains uncertain whether the association is a general phenomenon or driven by BD.
- Open Access
- 27 November 2023
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 10, e50072
Circadian Reinforcement Therapy in Combination With Electronic Self-Monitoring to Facilitate a Safe Postdischarge Period for Patients With Major Depression: Randomized Controlled Trial
Background: Patients with major depression exhibit circadian disturbance of sleep and mood, and when they are discharged from inpatient wards, this disturbance poses a risk of relapse. We developed a circadian reinforcement therapy (CRT) intervention to facilitate the transition from the inpatient ward to the home for these patients. CRT focuses on increasing the zeitgeber strength for the circadian clock through social contact, physical activity, diet, daylight exposure, and sleep timing. Objective: In this study, we aimed to prevent the worsening of depression after discharge by using CRT, supported by an electronic self-monitoring system, to advance and stabilize sleep and improve mood. The primary outcome, which was assessed by a blinded rater, was the change in the Hamilton Depression Rating Scale scores from baseline to the end point. Methods: Participants were contacted while in the inpatient ward and randomized 1:1 to the CRT or the treatment-as-usual (TAU) group. For 4 weeks, participants in both groups electronically self-monitored their daily mood, physical activity, sleep, and medication using the Monsenso Daybuilder (MDB) system. The MDB allowed investigators and participants to simultaneously view a graphical display of registrations. An investigator phoned all participants weekly to coinspect data entry. In the CRT group, participants were additionally phoned between the scheduled calls if specific predefined trigger points for mood and sleep were observed during the daily inspection. Participants in the CRT group were provided with specialized CRT psychoeducation sessions immediately after inclusion, focusing on increasing the zeitgeber input to the circadian system; a PowerPoint presentation was presented; paper-based informative materials and leaflets were reviewed with the participants; and the CRT principles were used during all telephone consultations. In the TAU group, phone calls focused on data entry in the MDB system. When discharged, all patients were treated at a specialized affective disorders service. Results: Overall, 103 participants were included. Participants in the CRT group had a significantly larger reduction in Hamilton Depression Scale score (P=.04) than those in the TAU group. The self-monitored MDB data showed significantly improved evening mood (P=.02) and sleep quality (P=.04), earlier sleep onset (P=.009), and longer sleep duration (P=.005) in the CRT group than in the TAU group. The day-to-day variability of the daily and evening mood, sleep offset, sleep onset, and sleep quality were significantly lower in the CRT group (all P<.001) than in the TAU group. The user evaluation was positive for the CRT method and the MDB system. Conclusions: We found significantly lower depression levels and improved sleep quality in the CRT group than in the TAU group. We also found significantly lower day-to-day variability in daily sleep, mood parameters, and activity parameters in the CRT group than in the TAU group. The delivery of the CRT intervention should be further refined and tested. Trial Registration: ClinicalTrials.gov NCT02679768; https://clinicaltrials.gov/study/NCT02679768 International Registered Report Identifier (IRRID): RR2-10.1186/s12888-019-2101-z
- 27 November 2023
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 10, e50072
Open AccessCircadian Reinforcement Therapy in Combination With Electronic Self-Monitoring to Facilitate a Safe Postdischarge Period for Patients With Major Depression: Randomized Controlled Trial
Background: Patients with major depression exhibit circadian disturbance of sleep and mood, and when they are discharged from inpatient wards, this disturbance poses a risk of relapse. We developed a circadian reinforcement therapy (CRT) intervention to facilitate the transition from the inpatient ward to the home for these patients. CRT focuses on increasing the zeitgeber strength for the circadian clock through social contact, physical activity, diet, daylight exposure, and sleep timing. Objective: In this study, we aimed to prevent the worsening of depression after discharge by using CRT, supported by an electronic self-monitoring system, to advance and stabilize sleep and improve mood. The primary outcome, which was assessed by a blinded rater, was the change in the Hamilton Depression Rating Scale scores from baseline to the end point. Methods: Participants were contacted while in the inpatient ward and randomized 1:1 to the CRT or the treatment-as-usual (TAU) group. For 4 weeks, participants in both groups electronically self-monitored their daily mood, physical activity, sleep, and medication using the Monsenso Daybuilder (MDB) system. The MDB allowed investigators and participants to simultaneously view a graphical display of registrations. An investigator phoned all participants weekly to coinspect data entry. In the CRT group, participants were additionally phoned between the scheduled calls if specific predefined trigger points for mood and sleep were observed during the daily inspection. Participants in the CRT group were provided with specialized CRT psychoeducation sessions immediately after inclusion, focusing on increasing the zeitgeber input to the circadian system; a PowerPoint presentation was presented; paper-based informative materials and leaflets were reviewed with the participants; and the CRT principles were used during all telephone consultations. In the TAU group, phone calls focused on data entry in the MDB system. When discharged, all patients were treated at a specialized affective disorders service. Results: Overall, 103 participants were included. Participants in the CRT group had a significantly larger reduction in Hamilton Depression Scale score (P=.04) than those in the TAU group. The self-monitored MDB data showed significantly improved evening mood (P=.02) and sleep quality (P=.04), earlier sleep onset (P=.009), and longer sleep duration (P=.005) in the CRT group than in the TAU group. The day-to-day variability of the daily and evening mood, sleep offset, sleep onset, and sleep quality were significantly lower in the CRT group (all P<.001) than in the TAU group. The user evaluation was positive for the CRT method and the MDB system. Conclusions: We found significantly lower depression levels and improved sleep quality in the CRT group than in the TAU group. We also found significantly lower day-to-day variability in daily sleep, mood parameters, and activity parameters in the CRT group than in the TAU group. The delivery of the CRT intervention should be further refined and tested. Trial Registration: ClinicalTrials.gov NCT02679768; https://clinicaltrials.gov/study/NCT02679768 International Registered Report Identifier (IRRID): RR2-10.1186/s12888-019-2101-z
- Open Access
- 20 June 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Circadian Reinforcement Therapy in Combination With Electronic Self-Monitoring to Facilitate a Safe Postdischarge Period for Patients With Major Depression: Randomized Controlled Trial (Preprint)
BACKGROUND Patients with major depression exhibit circadian disturbance of sleep and mood, and when they are discharged from inpatient wards, this disturbance poses a risk of relapse. We developed a circadian reinforcement therapy (CRT) intervention to facilitate the transition from the inpatient ward to the home for these patients. CRT focuses on increasing the zeitgeber strength for the circadian clock through social contact, physical activity, diet, daylight exposure, and sleep timing. OBJECTIVE In this study, we aimed to prevent the worsening of depression after discharge by using CRT, supported by an electronic self-monitoring system, to advance and stabilize sleep and improve mood. The primary outcome, which was assessed by a blinded rater, was the change in the Hamilton Depression Rating Scale scores from baseline to the end point. METHODS Participants were contacted while in the inpatient ward and randomized 1:1 to the CRT or the treatment-as-usual (TAU) group. For 4 weeks, participants in both groups electronically self-monitored their daily mood, physical activity, sleep, and medication using the Monsenso Daybuilder (MDB) system. The MDB allowed investigators and participants to simultaneously view a graphical display of registrations. An investigator phoned all participants weekly to coinspect data entry. In the CRT group, participants were additionally phoned between the scheduled calls if specific predefined trigger points for mood and sleep were observed during the daily inspection. Participants in the CRT group were provided with specialized CRT psychoeducation sessions immediately after inclusion, focusing on increasing the zeitgeber input to the circadian system; a PowerPoint presentation was presented; paper-based informative materials and leaflets were reviewed with the participants; and the CRT principles were used during all telephone consultations. In the TAU group, phone calls focused on data entry in the MDB system. When discharged, all patients were treated at a specialized affective disorders service. RESULTS Overall, 103 participants were included. Participants in the CRT group had a significantly larger reduction in Hamilton Depression Scale score (P=.04) than those in the TAU group. The self-monitored MDB data showed significantly improved evening mood (P=.02) and sleep quality (P=.04), earlier sleep onset (P=.009), and longer sleep duration (P=.005) in the CRT group than in the TAU group. The day-to-day variability of the daily and evening mood, sleep offset, sleep onset, and sleep quality were significantly lower in the CRT group (all P<.001) than in the TAU group. The user evaluation was positive for the CRT method and the MDB system. CONCLUSIONS We found significantly lower depression levels and improved sleep quality in the CRT group than in the TAU group. We also found significantly lower day-to-day variability in daily sleep, mood parameters, and activity parameters in the CRT group than in the TAU group. The delivery of the CRT intervention should be further refined and tested. CLINICALTRIAL ClinicalTrials.gov NCT02679768; https://clinicaltrials.gov/study/NCT02679768 INTERNATIONAL REGISTERED REPORT RR2-10.1186/s12888-019-2101-z
- 20 June 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCircadian Reinforcement Therapy in Combination With Electronic Self-Monitoring to Facilitate a Safe Postdischarge Period for Patients With Major Depression: Randomized Controlled Trial (Preprint)
BACKGROUND Patients with major depression exhibit circadian disturbance of sleep and mood, and when they are discharged from inpatient wards, this disturbance poses a risk of relapse. We developed a circadian reinforcement therapy (CRT) intervention to facilitate the transition from the inpatient ward to the home for these patients. CRT focuses on increasing the zeitgeber strength for the circadian clock through social contact, physical activity, diet, daylight exposure, and sleep timing. OBJECTIVE In this study, we aimed to prevent the worsening of depression after discharge by using CRT, supported by an electronic self-monitoring system, to advance and stabilize sleep and improve mood. The primary outcome, which was assessed by a blinded rater, was the change in the Hamilton Depression Rating Scale scores from baseline to the end point. METHODS Participants were contacted while in the inpatient ward and randomized 1:1 to the CRT or the treatment-as-usual (TAU) group. For 4 weeks, participants in both groups electronically self-monitored their daily mood, physical activity, sleep, and medication using the Monsenso Daybuilder (MDB) system. The MDB allowed investigators and participants to simultaneously view a graphical display of registrations. An investigator phoned all participants weekly to coinspect data entry. In the CRT group, participants were additionally phoned between the scheduled calls if specific predefined trigger points for mood and sleep were observed during the daily inspection. Participants in the CRT group were provided with specialized CRT psychoeducation sessions immediately after inclusion, focusing on increasing the zeitgeber input to the circadian system; a PowerPoint presentation was presented; paper-based informative materials and leaflets were reviewed with the participants; and the CRT principles were used during all telephone consultations. In the TAU group, phone calls focused on data entry in the MDB system. When discharged, all patients were treated at a specialized affective disorders service. RESULTS Overall, 103 participants were included. Participants in the CRT group had a significantly larger reduction in Hamilton Depression Scale score (P=.04) than those in the TAU group. The self-monitored MDB data showed significantly improved evening mood (P=.02) and sleep quality (P=.04), earlier sleep onset (P=.009), and longer sleep duration (P=.005) in the CRT group than in the TAU group. The day-to-day variability of the daily and evening mood, sleep offset, sleep onset, and sleep quality were significantly lower in the CRT group (all P<.001) than in the TAU group. The user evaluation was positive for the CRT method and the MDB system. CONCLUSIONS We found significantly lower depression levels and improved sleep quality in the CRT group than in the TAU group. We also found significantly lower day-to-day variability in daily sleep, mood parameters, and activity parameters in the CRT group than in the TAU group. The delivery of the CRT intervention should be further refined and tested. CLINICALTRIAL ClinicalTrials.gov NCT02679768; https://clinicaltrials.gov/study/NCT02679768 INTERNATIONAL REGISTERED REPORT RR2-10.1186/s12888-019-2101-z
- Open Access
- 19 November 2022
- Published by Elsevier in Neuroscience Applied
- Vol. 2
Associations between sleep quality and biomarkers for neurodegeneration - A longitudinal one-year case-control study of patients with bipolar disorder and healthy control individuals
- 19 November 2022
- Published by Elsevier in Neuroscience Applied
- Vol. 2
Open AccessAssociations between sleep quality and biomarkers for neurodegeneration - A longitudinal one-year case-control study of patients with bipolar disorder and healthy control individuals
- Open Access
- 1 January 2022
- Published by Elsevier in Journal of Affective Disorders
- Vol. 297, 623-633
Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study
- 1 January 2022
- Published by Elsevier in Journal of Affective Disorders
- Vol. 297, 623-633
Open AccessAlzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study